Journal of Viral Hepatitis

Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C
pp. 623-633(11)
Authors: Gambarin-Gelwan, M.; Jacobson, I. M.

Health care costs of persons with newly diagnosed hepatitis C virus: a population-based, observational study
pp. 634-640(7)
Authors: Nguyen, Thu-Ha; Jacobs, Philip; Hanrahan, Anita; Fraser-Lee, Nonie; Wong, Winnie; Lee, Bonita; Ohinmaa, Arto

Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin
pp. 641-645(5)
Authors: Weiland, O.; Hollander, A.; Mattsson, L.; Glaumann, H.; Lindahl, K.; Schvarcz, R.; Lindh, G.; Enquist, R.; Quist, A.

Could the depression of obese patients suffering from chronic hepatitis C be temporarily improved?
pp. 646-650(5)
Authors: Tarantino, G.; Basile, V.; Conca, P.; Ariello, M.; Minno, M. N. D. Di; Romano, A.; Gentile, A.; Capone, D.

Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin
pp. 651-658(8)
Authors: Toyoda, H.; Kumada, T.; Kiriyama, S.; Sone, Y.; Tanikawa, M.; Hisanaga, Y.; Kanamori, A.; Atsumi, H.; Nakano, S.; Arakawa, T.; Honda, T.; Hayashi, K.; Katano, Y.; Goto, H.

Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C
pp. 659-665(7)
Authors: Scherzer, T.-M.; Reddy, K. R.; Wrba, F.; Hofer, H.; Staufer, K.; Steindl-Munda, P.; Gangl, A.; Ferenci, P.

Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection
pp. 666-674(9)
Authors: Schiavon, L. L.; Narciso-Schiavon, J. L.; Carvalho Filho, R. J.; Sampaio, J. P.; Medina-Pestana, J. O.; Lanzoni, V. P.; Silva, A. E. B.; Ferraz, M. L. G.

Branched oligosaccharide structures on HBV prevent interaction with both DC-SIGN and L-SIGN
pp. 675-683(9)
Authors: Op den Brouw, M. L.; de Jong, M. A. W. P.; Ludwig, I. S.; van der Molen, R. G.; Janssen, H. L. A.; Geijtenbeek, T. B. H.; Woltman, A. M.

Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B: a prospective controlled study
pp. 684-689(6)
Authors: Luo, K.; Mao, Q.; Karayiannis, P.; Liu, D.; Liu, Z.; Zhou, Y.; Feng, X.; Zhu, Y.; Guo, Y.; Jiang, R.; Zhou, F.; Peng, J.; Hou, J.

The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use
pp. 690-698(9)
Authors: Tseng, F.-C.; Edlin, B. R.; Zhang, M.; Kral, A.; Busch, M. P.; Ortiz-Conde, B. A.; Welzel, T. M.; O'Brien, T. R.